Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A novel reduce toxity myeloablative conditioning regimen f-BMT improves efficacy and safety of allogeneic hematopoietic stem cell transplantation in patients with transfusion-dependent thalassemia: A multicenter clinical trial

View Full Paper
Ask AI
Bookmark
Share

Authors

GLGuiping LiaoYZYali ZhouLDLan Deng

Discussion

Loading...

Member takes

Overview

Multicenter clinical trial shows improved efficacy and reduced graft versus host disease in thalassemia patients receiving F-BMT regimen.

Key Points

  • The aim of the research is to evaluate the safety and efficacy of the F-BMT conditioning regimen in thalassemia patients post-transplant.
  • Conducted a multicenter clinical trial at multiple hospitals with patients aged 3-25 years.
  • Evaluated outcomes of F-BMT regimen in patients with transfusion-dependent thalassemia.
  • Monitored graft versus host disease and overall patient survival.
  • Analyzed engraftment rates and incidences of infections, complications, and viral reactivation.
  • 1-year thalassemia-free survival was 94.24% and overall survival was 96.44%.
  • Graft versus host disease incidence was low, with only 7.1% experiencing grade II-IV aGVHD.
  • Engraftment rate by day +28 post-transplant was 97.78%.
  • Viral reactivation occurred in 26% of patients, with notable cases of CMV and EBV reactivation.

Cite This Study

Liao et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d302https://doi.org/10.1182/blood-2025-729
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Fludarabine, Busulfan, Thiotepa, and Melphalan: A Novel Low‐Toxicity Myeloablative Conditioning Regimen for Haploidentical HSCT in Children and Adolescents Aged ≥7 Years With Transfusion‐Dependent β‐Thalassemia2026
  2. 2Analysis of efficacy and prognostic factors in transfusion-dependent thalassemia following allogeneic hematopoietic stem cell transplantation using the ‘gx-07-tm’ regimen2025
  3. 3The efficacy and safety of using low-dose cyclophosphamide, fludarabine and thymoglobulin in allogeneic hematopoietic stem cell transplantation for transfusion-dependent non-severe aplastic anemia：a retrospective study.2025
  4. 4Enhanced engraftment and immune recovery in thalassemia via optimized conditioning for TCRαβ⁺-depleted haploidentical transplants2025
  5. 5An evolving landscape – how changing conditioning regimes can improve myelofibrosis transplant outcomes.2025